Resistance Measured by Airflow Perturbation Compared with Standard Pulmonary Function Measures

Tania Haque¹, Jafar Vossoughi², Arthur T. Johnson³, Wanda Bell-Farrell¹, Thomas Fitzgerald¹, Steven M. Scharf¹#

¹University of Maryland, Baltimore, USA
²Engineering and Scientific Research Associates, Olney, USA
³Fischell Department of Bioengineering University of Maryland, College Park, USA
Email: #sscharf@medicine.umaryland.edu

Received March 5, 2013; revised April 5, 2013; accepted April 13, 2013

ABSTRACT

Background: Routine lung function testing requires expensive equipment, or requires maximum expiratory effort. The airflow perturbation device (APD) is a light handheld device, allowing for serial measures of respiratory resistance noninvasively and effortlessly.

Methods: In a convenience sample of 398 patients undergoing pulmonary function testing, we compared routine spirometric indices (forced expired volume in 1 second (FEV₁), peak expiratory flow (PEF)), and airways resistance (Raw-272 patients), to measures of respiratory resistance measured with the APD including inspiratory (IR), expiratory (ER) and averaged (AR) resistance.

Results: Measures of lung function were significantly correlated (p < 0.001). On regression analysis, between 7% - 17% of the variance (R²) for FEV₁, PEF, and Raw was explained by APD measurements. Approximately 2/3 of the variance in FEV₁ was explained by PEF measurements.

Conclusions: APD measurements of lung function correlate with conventional measures. Future studies should be directed at exploring the use of the APD device in serial measures of lung function in patients with lung disease.

Keywords: Airflow Perturbation Device; Pulmonary Function; Forced Expired Volume in 1 Second; Peak Expiratory Flow; Airway Resistance

1. Introduction

Airway resistance is a commonly used measurement of lung function in a variety of respiratory disorders. Resistance measurement is also useful in evaluating respiratory effects of exposure to bronchoconstrictive or bronchodilatory drugs as well as to airborne pollutants.

Whole-body plethysmography is commonly used to measure airways resistance [1]. This technique requires coordinated breathing maneuvers coached by a skilled technician and a large non-portable and expensive apparatus. Another technique for measurement of pulmonary resistance (airways resistance and lung tissue resistance) is the technique of von Niergard and Wirz [2]. However, this technique necessitates the subject swallowing an uncomfortable esophageal balloon. Finally, forced oscillation, originally designed to measure respiratory impedance during tidal breathing [3] has been shown to be sensitive to changes in airways resistance [4]. For this technique, sinusoidal oscillations of pressure are superimposed on tidal breathing. From the ratio of pressure changes to flow changes and the phase angles between them, impedance is calculated [4]. However, forced oscillation requires expensive equipment and is only suitable in the pulmonary function laboratory. In the clinical setting, total respiratory resistance is usually assessed indirectly using spirometric indices such as forced expired volume in one second (FEV₁) or peak expiratory flow (PEF), the latter often used at home. However, spirometric techniques require forced exhalation, require some patient training, and may be difficult or stressful for some patients to perform. Thus, most techniques for measurement of pulmonary resistance require either skilled cooperation on the part of the subject and/or specialized expensive equipment found in pulmonary function laboratories and are not suitable for home measurement.

The airflow perturbation device (APD—see Figure 1) is a variant of the forced oscillation technique suitable for use in settings outside the pulmonary function laboratory.
This lightweight, handheld, noninvasive, portable and fast device measures total respiratory resistance during quiet tidal breathing, without the need for special breathing maneuvers. The APD has been shown to measure total respiratory resistance from the mouth to the surface of the chest wall [6,7]; it thus includes airways, lung tissue, and chest wall resistance components. A segmented wheel rotating in the air pathway from the mouth causes changes at 10 Hz in both airflow and mouth pressure. When airflow diminishes, mouth pressure increases and vice versa. From the ratio of the amplitudes of pressure and flow perturbations, total respiratory resistance can be calculated. The APD separates respiratory resistance during inhalation from that during exhalation. This feature can be of importance for diagnosis of particular respiratory pathologies—e.g. exercise-induced paradoxical vocal fold motion that primarily affects the inspiratory phase. Additionally, the APD is small and portable, thus making it suitable for use away from the health care facility (Figure 2).

The APD device and the principles behind it have been described in detail elsewhere [5-9]. Coursey et al. [8] showed that APD derived measurements of respiratory resistance reflected changes in added resistances at least as well as classic measurements of pulmonary resistance using the esophageal balloon [2]. APD measured respiratory resistance was not significantly different from pulmonary resistance measured using the esophageal balloon. In fact, with added external resistance, the differences between APD and pulmonary resistance decreased. These authors also demonstrated that expiratory isovolume pressure-flow curves could reliably be obtained with the APD technique [9].

The APD offers a number of potential advantages for the frequent following of lung function in patients with pulmonary disease. First, it requires no cumbersome equipment. Second, it requires no complicated maneuvers like panting or forced expiration. Finally, it does not require a forced expiration like FEV1 or PEF. Thus APD measurement would seem to be ideal to use as an out of hospital assessment of lung function.

The current study is designed to compare measurements of respiratory resistance using the APD with commonly used indices of lung function, based on spirometry or body plethysmography, in adults referred to the pulmonary function laboratory for evaluation of lung function. We hypothesized that APD measurements of resistance would be significantly correlated with standard laboratory measures of lung function.

2. Methods

The protocol was approved by the University of Maryland Institutional Review Board. Inclusion criteria included: age ≥ 18, and willingness and ability to sign informed consent in the English language. Patients were excluded if they appeared to have an unstable pulmonary condition requiring referral to urgent care. A convenience sample of 398 patients, aged 18 to 88, with a variety of pulmonary complaints, referred to the pulmonary function laboratory for routine pulmonary function testing by their providers was studied. All subjects underwent spirometric testing. In 272, body plethysmography was also performed allowing for measurements of lung volume and airways resistance [10], and in 23 spirmetry and APD measures were repeated following bronchodil-
lator. Since the laboratory performed only those tests requested by the referring provider, we could not add to these numbers. Following measurements of lung function as ordered by their provider, subjects were asked to quietly breathe through the airflow perturbation device for one minute in the sitting position. A nose clip was used to obstruct nasal breathing. In some cases, APD measurements were performed twice on the same day: following spirometry before bronchodilator and following spirometry after bronchodilator.

Spirometry and body plethysmography were performed using a SensorMedics ViAsys system according to the standards set out by the American Thoracic Society/European Respiratory Society [11,12]. Spirometry yielded values for FEV1, forced vital capacity (FVC) and PEF. Body plethysmography yielded values for lung volumes including functional residual capacity (FRC), airways resistance (Raw), and specific airways conductance (sGaw = 1/Raw/FRC). Predicted values for spirometry and body plethysmograph measurements were generated using standard published equations [13,14]. For APD measurements, we used a lightweight handheld APD device (see Figure 2). Patients breathed normally for 1 minute through the APD while their nostrils were blocked with a nose clip. No special breathing maneuvers were required. APD measurements yielded values for inspiratory (IR) and expiratory resistance (ER) as well as respiratory resistance averaged over the entire respiratory cycle (AR).

**Data Analysis**

Data were collected and collated. Central tendency was estimated as the mean and variability as standard deviation as all data were normally distributed (Shapiro-Wilk test). Differences between multiple means were assessed using one-way analysis of variance for repeated measures. If significance was found, we used post-hoc testing (Neuman-Keuls) to determine the source of the significance. Associations between variables were assessed using the Least-Squares technique and Pearson coefficients were calculated. For most analyses, linear regression yielded the greatest correlation. SigmaPlot 12.2 (Systat software, Inc.—Chicago, Ill) was used to perform all statistical analyses. The null hypothesis was rejected at the 5% level.

**3. Results**

The sample was composed of 46% males and included 52% Caucasian, 44% African American and 3% from other ethnicities. One-hundred and nineteen were former or current smokers (mean smoking history = 26.2 ± 22.6 pack-years). **Table 1** shows anthropomorphic data as well as average prebronchodilator lung function measures. There were no significant differences between mean Raw and AR, IR or ER. A total of 137/398 patients had “obstructive” physiology, defined as FEV1/FVC less than 70%. A total of 126/398 patients had “restrictive” physiology, defined as FEV1/FVC > 70% and FVC < 80% predicted.

**Table 2** shows correlations between the different variable measured. All correlations were significant (p < 0.001). Also shown are the values for $R^2$. This is the proportion of the variance in the dependent variable explained by the independent variable. For correlations between APD measurements and either FEV1 or PEF, $R^2$ (percent of explained variance) was in the 7% - 12% range. For the correlation between APD measurements and Raw (plethysmograph) $R^2$ was 15% - 17%. Also shown in **Table 2** are correlations between the APD measurements AR, IR and ER. As expected, these indicated a tight correlation between the various APD measures of respiratory resistance, with the variability in one measure accounting for 68% - 92% of the variance in the other. **Figure 3** shows the regression of AR on FEV1. When we compared FEV1 (an expiratory maneuver), to ER a similar regression was found (Figure 4). Correlations between FEV1 and APD measurements and PEF and APD measurements were in the expected direction.
Table 2. Correlation coefficients between different measures of lung function were calculated and shown below.

<table>
<thead>
<tr>
<th></th>
<th>PEF (L/sec)</th>
<th>Raw (cm H₂O/L/s)</th>
<th>IR (cm H₂O/L/s)</th>
<th>ER (cm H₂O/L/s)</th>
<th>AR (cm H₂O/L/s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>FEV₁ (L)</td>
<td>0.82</td>
<td>-0.44</td>
<td>-0.31</td>
<td>-0.35</td>
<td>-0.35</td>
</tr>
<tr>
<td></td>
<td>R² = 0.68</td>
<td>R² = 0.19</td>
<td>R² = 0.10</td>
<td>R² = 0.12</td>
<td>R² = 0.12</td>
</tr>
<tr>
<td>PEF (L/sec)</td>
<td>-0.42</td>
<td>-0.20</td>
<td>-0.31</td>
<td>-0.31</td>
<td>-0.31</td>
</tr>
<tr>
<td></td>
<td>R² = 0.18</td>
<td>R² = 0.08</td>
<td>R² = 0.09</td>
<td>R² = 0.07</td>
<td>R² = 0.07</td>
</tr>
<tr>
<td>Raw (cm H₂O/L/s)</td>
<td></td>
<td>0.39</td>
<td>0.39</td>
<td>0.41</td>
<td></td>
</tr>
<tr>
<td></td>
<td>R² = 0.15</td>
<td>R² = 0.153</td>
<td>R² = 0.17</td>
<td></td>
<td></td>
</tr>
<tr>
<td>IR (cm H₂O/L/s)</td>
<td></td>
<td>0.83</td>
<td>0.95</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>R² = 0.69</td>
<td>R² = 0.90</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ER (cm H₂O/L/s)</td>
<td></td>
<td></td>
<td></td>
<td>0.96</td>
<td>R² = 0.92</td>
</tr>
</tbody>
</table>

For abbreviations see previous table. All correlations were significant to the p < 0.001 level.

Figure 3. Regression of AR on FEV₁; AR = 3.883 - (0.412 × FEV₁); R² = 0.124; p < 0.001.

Figure 4. Regression of ER on FEV₁; ER = 4.085 - (0.465 × FEV₁); R² = 0.123; p < 0.001.

i.e. as FEV₁ or PEF increased (improved function), APD resistance decreased. Figure 5 shows the regression of AR on Raw (all measured prebronchodilator). While the correlation was significant with similar correlation coefficients as in Figures 3 and 4, it was clear that there was a great degree of leverage in points towards the extremes of each. The correlation between 2 commonly used indices of lung function, FEV₁ and PEF (Table 2) showed that some 2/3 of the variance of one was explained by the other.

Finally, we compared bronchodilator associated changes in indices of lung function between FEV₁ and APD measurements. The mean change in FEV₁ with bronchodilator in the 28 patients in whom data were obtained pre and post bronchodilator was relatively small: 0.10 ± 0.23 L. The correlations between changes in APD measurements and FEV₁ were not significant: For ER: \( \Delta ER = 0.0486 - (0.264 \times \Delta FEV₁), R = 0.103, \) NS; For AR: \( \Delta AR = 0.00279 - (0.140 \times \Delta FEV₁), R = 0.063; \) For IR: \( \Delta IR = 0.0257 - (0.416 \times \Delta FEV₁), R = 0.178. \)

4. Discussion

We compared measurements commonly used to assess lung function in the pulmonary function laboratory with those obtained using the APD. While significant correlations were found, only 7% - 17% of the variance in APD measurements was explained by FEV₁, PEF or Raw. Further, there was no correlation between the change in FEV₁ and APD measurements with bronchodilator. In the ensuing discussion we review these findings in the light of the current available literature.

To our knowledge this is the largest group of subjects in which changes in APD and other assessments of lung function were compared. Further, the other studies cited included normal healthy subjects. The current study includes unselected patients referred to the pulmonary function lab for a variety of indications as determined by their attending providers.

As shown by the figures and Table 2, the correlations with FEV₁, PEF, and Raw, although going in the expected directions, and statistically significant, are not tight, with only 7% - 17% of the variance of one being explained by the other. By contrast, the correlation be-
between FEV$_1$ and PEF, that are forced expiratory maneuvers, was excellent, with some 2/3 of the variance in one explained by the other.

It is important to bear in mind that the various measures of pulmonary function actually measure different aspects of respiratory mechanics. FEV$_1$ and PEF are certainly responsive to changes in airways resistance; however, they are also very dependent on patient effort. Raw, measured in the body plethysmograph, is sensitive to changes in flow-resistance of the airways, but excludes lung and chest wall tissue resistance. The APD measures total respiratory resistance, and includes a large component of upper airways resistance (see [8]). The most practical use for the APD would likely be to follow patients with lung disease serially at home given the ease of use and low cost of this device. We had hoped that the measurement of serial function before and after bronchodilator would simulate serial measurements for standard spirometry compared with APD. Unfortunately, few patients had bronchodilator studies ordered, and the overall change in FEV$_1$ with bronchodilator was small (approximately 100 cc). Finally, in a recent study [15], the intrasubject variability of APD measurements was assessed. It was found that the largest portion of the variability of measurements was in fact due to changes within the subject and not to changes within the APD, strengthening our argument that the device would be most useful for serial measurements in patients with lung disease.

In sum, there are significant correlations between APD derived measures of respiratory resistance and measures derived from standard pulmonary function testing. The variance explained was less than that between commonly used measures of pulmonary function. Studies should be directed at the evaluation of efficacy of serial measurements over time in patients with respiratory disease.

REFERENCES


